Kyprolis-Dexamethasone Combo Allows Relapsed Myeloma Patients to Live Longer, Amgen Says
Kyprolis (carfilzomib), when given with dexamethasone, lets relapsed myeloma patients live an average 7.6 months longer than those treated with  Velcade (bortezomib) with dexamethasone — information that …